Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

Ryan K. Shields, Brian A. Potoski, Ghady Haidar, Binghua Hao, Yohei Doi, Liang Chen, Ellen G. Press, Barry N. Kreiswirth, Cornelius J. Clancy, M. Hong Nguyen

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

Original languageEnglish
Pages (from-to)1615-1618
Number of pages4
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume63
Issue number12
DOIs
Publication statusPublished - 15-12-2016
Externally publishedYes

Fingerprint

Enterobacteriaceae Infections
Carbapenems
Drug-Related Side Effects and Adverse Reactions
Enterobacteriaceae
Survival Rate
ceftazidime drug combination avibactam

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Shields, Ryan K. ; Potoski, Brian A. ; Haidar, Ghady ; Hao, Binghua ; Doi, Yohei ; Chen, Liang ; Press, Ellen G. ; Kreiswirth, Barry N. ; Clancy, Cornelius J. ; Nguyen, M. Hong. / Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 ; Vol. 63, No. 12. pp. 1615-1618.
@article{bfdf1e1245454a5e9de1632563562990,
title = "Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections",
abstract = "Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59{\%} (22/37) and 76{\%} (28/37), respectively. In 23{\%} (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27{\%} (10/37). Ceftazidime-avibactam resistance was detected in 30{\%} (3/10) of microbiologic failures.",
author = "Shields, {Ryan K.} and Potoski, {Brian A.} and Ghady Haidar and Binghua Hao and Yohei Doi and Liang Chen and Press, {Ellen G.} and Kreiswirth, {Barry N.} and Clancy, {Cornelius J.} and Nguyen, {M. Hong}",
year = "2016",
month = "12",
day = "15",
doi = "10.1093/cid/ciw636",
language = "English",
volume = "63",
pages = "1615--1618",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "12",

}

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. / Shields, Ryan K.; Potoski, Brian A.; Haidar, Ghady; Hao, Binghua; Doi, Yohei; Chen, Liang; Press, Ellen G.; Kreiswirth, Barry N.; Clancy, Cornelius J.; Nguyen, M. Hong.

In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 63, No. 12, 15.12.2016, p. 1615-1618.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

AU - Shields, Ryan K.

AU - Potoski, Brian A.

AU - Haidar, Ghady

AU - Hao, Binghua

AU - Doi, Yohei

AU - Chen, Liang

AU - Press, Ellen G.

AU - Kreiswirth, Barry N.

AU - Clancy, Cornelius J.

AU - Nguyen, M. Hong

PY - 2016/12/15

Y1 - 2016/12/15

N2 - Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

AB - Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

UR - http://www.scopus.com/inward/record.url?scp=84995524184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995524184&partnerID=8YFLogxK

U2 - 10.1093/cid/ciw636

DO - 10.1093/cid/ciw636

M3 - Article

C2 - 27624958

AN - SCOPUS:84995524184

VL - 63

SP - 1615

EP - 1618

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 12

ER -